Senai Cimatec
🇸🇻El Salvador
- Country
- 🇸🇻El Salvador
- Ownership
- Private
- Established
- 2002-01-01
- Employees
- 501
- Market Cap
- -
Clinical Trials
3
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)Autologous Bone Marrow Stem Cell Transplantation in Patients With Subacute Spinal Cord Injury
Phase 2
Not yet recruiting
- Conditions
- Spinal Cord Injuries
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- SENAI CIMATEC
- Target Recruit Count
- 40
- Registration Number
- NCT05671796
- Locations
- 🇧🇷
Senai Cimatec, Salvador, Bahia, Brazil
Clinical Study to Evaluate the Effect of Food Supplement in People Infected With Coronavirus
Phase 2
Completed
- Conditions
- COVID-19 Virus Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- SENAI CIMATEC
- Target Recruit Count
- 224
- Registration Number
- NCT05446961
- Locations
- 🇧🇷
Senai Cimatec, Salvador, Bahia, Brazil
Study to Assess Safety, Reactogenicity and Immunogenicity of the VACCINE RNA MCTI CIMATEC HDT (HDT-301) Vaccine Against COVID-19
Phase 1
- Conditions
- SARS-CoV-2
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- SENAI CIMATEC
- Target Recruit Count
- 90
- Registration Number
- NCT04844268
- Locations
- 🇧🇷
Hospital da Bahia, Salvador, Bahia, Brazil
News
No news found